CSPIA
RETA

Cary Street Partners Investment Advisory’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-32,472
Closed -$4.01M – 424
2020
Q4 		$4.01M Buy
+32,472
New +$4.27M 0.77% 26

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Cary Street Partners Investment Advisory's RETA Position: Q1 2021 in Review

Cary Street Partners Investment Advisory sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2021, closing a stake of 32,472 shares — an estimated $4.01M sold.

Cary Street Partners Investment Advisory first reported a position in RETA in Q4 2020 and held it in 1 quarter. The position peaked at $4.01M in Q4 2020. 201 funds tracked by Wall St. Rank hold RETA as of Q1 2021.

  • Cary Street Partners Investment Advisory reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 32,472 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2021, an estimated $4.01M.
  • Cary Street Partners Investment Advisory first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 1 quarter.
  • Cary Street Partners Investment Advisory's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.01M in Q4 2020.
  • 201 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2021.

Based on Cary Street Partners Investment Advisory's 13F filing for Q1 2021, filed 17 May 2021.